Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1979 1
1980 4
1981 1
1982 3
1983 1
1985 3
1986 5
1987 4
1988 2
1989 1
1990 4
1991 2
1992 8
1993 7
1994 8
1995 4
1996 7
1997 7
1998 14
1999 6
2000 13
2001 25
2002 29
2003 34
2004 48
2005 51
2006 39
2007 59
2008 77
2009 97
2010 96
2011 135
2012 149
2013 172
2014 216
2015 259
2016 322
2017 365
2018 413
2019 470
2020 628
2021 703
2022 322
Text availability
Article attribute
Article type
Publication date

Search Results

4,325 results
Results by year
Filters applied: . Clear all
Page 1
METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis.
Su R, Dong L, Li Y, Gao M, He PC, Liu W, Wei J, Zhao Z, Gao L, Han L, Deng X, Li C, Prince E, Tan B, Qing Y, Qin X, Shen C, Xue M, Zhou K, Chen Z, Xue J, Li W, Qin H, Wu X, Sun M, Nam Y, Chen CW, Huang W, Horne D, Rosen ST, He C, Chen J. Su R, et al. Among authors: zhou k. Nat Cell Biol. 2022 Feb;24(2):205-216. doi: 10.1038/s41556-021-00835-2. Epub 2022 Feb 10. Nat Cell Biol. 2022. PMID: 35145225
Sestrin2 in atherosclerosis.
Tian Z, Yan BJ, Luo W, Gui DD, Zhou K, Tian KJ, Ma Y, Zhou ZX, Jiang ZS. Tian Z, et al. Among authors: zhou k. Clin Chim Acta. 2021 Dec;523:325-329. doi: 10.1016/j.cca.2021.10.019. Epub 2021 Oct 16. Clin Chim Acta. 2021. PMID: 34666031 Review.
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Opat S, et al. Among authors: zhou ks. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: zhou k. Breast Cancer Res Treat. 2021 Oct;189(3):689-699. doi: 10.1007/s10549-021-06334-0. Epub 2021 Aug 19. Breast Cancer Res Treat. 2021. PMID: 34414532 Free PMC article. Clinical Trial.
Monoterpenoid biosynthesis by engineered microbes.
Liu Y, Ma X, Liang H, Stephanopoulos G, Zhou K. Liu Y, et al. Among authors: zhou k. J Ind Microbiol Biotechnol. 2021 Dec 23;48(9-10):kuab065. doi: 10.1093/jimb/kuab065. J Ind Microbiol Biotechnol. 2021. PMID: 34601590 Review.
4,325 results